ArticlePLoS neglected tropical diseases2019
Performance of serological tests available in Brazil for the diagnosis of human visceral leishmaniasis.
Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Global Landscape of Molecular and Immunological Diagnostic Tests for Human Leishmaniasis: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2025Pooled it
- Diagnosis of visceral and cutaneous leishmaniasis using loop-mediated isothermal amplification (LAMP) protocols: a systematic review and meta-analysis.Parasites & vectors · 2022Pooled it
- Evaluation of a new rapid diagnostic test, based on the chimeric protein Q5, for the diagnosis of human and canine forms of visceral leishmaniasis.Memorias do Instituto Oswaldo Cruz · 2026Article
- Molecular diagnostics for cutaneous leishmaniasis: progress towards fulfilling the WHO target product profile.Parasitology · 2025Review
- Impact of age and immune status on the accuracy of rapid diagnostic tests for visceral leishmaniasis in Brazil.PLoS neglected tropical diseases · 2025Article
- Performance of Extracellular Vesicles FromJournal of parasitology research · 2025Article
- Exploring Bioinformatics Solutions for Improved Leishmaniasis Diagnostic Tools: A Review.Molecules (Basel, Switzerland) · 2024Review
- Serological Screening and Risk Factors Associated withMicroorganisms · 2024Article
- An algorithm for visceral leishmaniasis diagnosis in Brazil from a 10-year analysis of National Reference Laboratory data.Parasitology research · 2024Article
- Accuracy of serological tests in diagnosing mucosal leishmaniasis.Parasitology research · 2023Article
- Disposable electrochemical platform based on solid-binding peptides and carbon nanomaterials: an alternative device for leishmaniasis detection.Mikrochimica acta · 2023Article
- rMELEISH: A Novel Recombinant Multiepitope-Based Protein Applied to the Serodiagnosis of Both Canine and Human Visceral Leishmaniasis.Pathogens (Basel, Switzerland) · 2023Article
- Recombinant protein KR95 as an alternative for serological diagnosis of human visceral leishmaniasis in the Americas.PloS one · 2023Article
- Serology for visceral leishmaniasis: How trusty is the accuracy reported by the manufacturers?Revista da Sociedade Brasileira de Medicina Tropical · 2023Review
- Visceral Leishmaniasis Associated with HIV Coinfection in Pará, Brazil.HIV/AIDS (Auckland, N.Z.) · 2023Article
- First molecular-based detection study of Leishmania infantum in the Tapirapé indigenous population in the Brazilian Amazon.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2022Article
- Pediatric visceral leishmaniasis: a retrospective study to propose the diagnostic tests algorithm in southern Iran.Parasitology research · 2021Article
- Article
- Improved Performance of ELISA and Immunochromatographic Tests Using a New Chimeric A2-Based Protein for Human Visceral Leishmaniasis Diagnosis.Journal of immunology research · 2021Observational
- Molecular Tracking of theFrontiers in cellular and infection microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVisceral leishmaniasis (VL) is the most severe form of leishmaniasis and is potentially fatal if not diagnosed and treated. Accurate and timely diagnosis is considered one of the pillars needed for the reduction in disease-related lethality. Brazil is currently one of the three eco-epidemiological hotspots for this disease. Several serological tests are commercially available in this country for VL diagnosis, although information on the performance of these tests is fragmented and insufficient. The aim of this study was to directly compare the performance of six commercial kits: three enzyme-linked immunosorbent assays (ELISAs), two immunofluorescence antibody tests (IFATs), one immunochromatographic test (ICT), besides one ICT, currently not commercially available in Brazil and one in-house direct agglutination test (DAT-LPC), not yet marketed. METHODOLOGY/PRINCIPAL
findingsA panel of 236 stored samples from patients with clinically suspected VL, including 77 HIV-infected patients, was tested. IT-LEISH and DAT-LPC showed the highest accuracy rate among the non-HIV-infected patients, 96.2% [CI95%: 92.8-99.7%] and 95.6% [CI95%: 91.9-99.3%], respectively. For the ELISA tests evaluated, the maximum accuracy was 91.2%, and in the inter HIV-status group analysis, no significant differences were observed. For both IFATs evaluated, the maximum accuracy was 84.3%, and a lower accuracy rate was observed among the HIV-infected patients (p = 0.039) than among the non-HIV-infected patients. The DAT-LPC was the most accurate test in the HIV-infected patients (p≤0.115). In general, no significant difference in accuracy was observed among the VL-suspected patients stratified by age. CONCLUSIONS/SIGNIFICANCE: In summary, the differences in the performance of the tests available for VL in Brazil confirm the need for local studies before defining the diagnostic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.